Tumor-Educated Platelets lncRNA-STARD4-AS1 and ELOA-AS1 as Potential Novel Biomarkers for the Early Diagnosis of Non-Small Cell Lung Cancer.

IF 2.5 4区医学 Q3 ONCOLOGY Cancer Management and Research Pub Date : 2025-01-03 eCollection Date: 2025-01-01 DOI:10.2147/CMAR.S498516

ChangLiang Luo, Zhongyuan Lin, Fangfang Huang, Leping Ning, Yulin Yuan

{"title":"Tumor-Educated Platelets lncRNA-STARD4-AS1 and ELOA-AS1 as Potential Novel Biomarkers for the Early Diagnosis of Non-Small Cell Lung Cancer.","authors":"ChangLiang Luo, Zhongyuan Lin, Fangfang Huang, Leping Ning, Yulin Yuan","doi":"10.2147/CMAR.S498516","DOIUrl":null,"url":null,"abstract":"Purpose: (Tumor-educated platelets) TEPs have emerged as active players in all steps of tumorigenesis, confrontation of platelets with tumor cells via transfer of tumor-associated biomolecules and results in the sequestration of such biomolecules. The current study was aimed to examine whether TEPs lncRNA-STARD4-AS1 and ELOA-AS1 might be potential biomarkers for NSCLC.Materials and methods: TEPs were obtained by low-speed centrifugation. Quantitative real-time PCR was used to determine the expression level of TEPs-STARD4-AS1, ELOA-AS1 in the training cohort and the validation cohort. ROC curve was generated to evaluate their diagnostic value. Correlations between TEPs-STARD4-AS1, ELOA-AS1 and clinical parameters were further analyzed.Results: Our results showed that the level of TEPs-STARD4-AS1 and ELOA-AS1 significantly upregulated in patients with NSCLC compared with healthy controls in the two cohorts. By ROC analysis, we found that TEPs-STARD4-AS1, ELOA-AS1 could offer valuable diagnostic performance for NSCLC patients (AUCSTARD4-AS1 = 0.800/0.774, and AUCELOA-AS1 = 0.754/0.718 for diagnosing adenocarcinoma and squamous cell carcinoma cases from controls, respectively). The combination of TEP-STARD4-AS1 and ELOA-AS1 improved the diagnostic efficiency of NSCLC. Clinicopathological analysis further revealed that TEPs-STARD4-AS1 level significantly correlated with tumor-node-metastasis (TNM) stage (p = 0.011), while TEPs-ELOA-AS1 expression significantly correlated with tumor-node-metastasis (TNM) stage and (p = 0.019) distant metastasis (p = 0.004).Conclusion: Our data suggested that TEPs-STARD4-AS1 and ELOA-AS1 are promising non-invasive circulating diagnostic markers for NSCLC.","PeriodicalId":9479,"journal":{"name":"Cancer Management and Research","volume":"17 ","pages":"1-9"},"PeriodicalIF":2.5000,"publicationDate":"2025-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11705986/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Management and Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/CMAR.S498516","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: (Tumor-educated platelets) TEPs have emerged as active players in all steps of tumorigenesis, confrontation of platelets with tumor cells via transfer of tumor-associated biomolecules and results in the sequestration of such biomolecules. The current study was aimed to examine whether TEPs lncRNA-STARD4-AS1 and ELOA-AS1 might be potential biomarkers for NSCLC.

Materials and methods: TEPs were obtained by low-speed centrifugation. Quantitative real-time PCR was used to determine the expression level of TEPs-STARD4-AS1, ELOA-AS1 in the training cohort and the validation cohort. ROC curve was generated to evaluate their diagnostic value. Correlations between TEPs-STARD4-AS1, ELOA-AS1 and clinical parameters were further analyzed.

Results: Our results showed that the level of TEPs-STARD4-AS1 and ELOA-AS1 significantly upregulated in patients with NSCLC compared with healthy controls in the two cohorts. By ROC analysis, we found that TEPs-STARD4-AS1, ELOA-AS1 could offer valuable diagnostic performance for NSCLC patients (AUC_STARD4-AS1 = 0.800/0.774, and AUC_ELOA-AS1 = 0.754/0.718 for diagnosing adenocarcinoma and squamous cell carcinoma cases from controls, respectively). The combination of TEP-STARD4-AS1 and ELOA-AS1 improved the diagnostic efficiency of NSCLC. Clinicopathological analysis further revealed that TEPs-STARD4-AS1 level significantly correlated with tumor-node-metastasis (TNM) stage (p = 0.011), while TEPs-ELOA-AS1 expression significantly correlated with tumor-node-metastasis (TNM) stage and (p = 0.019) distant metastasis (p = 0.004).

Conclusion: Our data suggested that TEPs-STARD4-AS1 and ELOA-AS1 are promising non-invasive circulating diagnostic markers for NSCLC.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

肿瘤诱导血小板lncRNA-STARD4-AS1和ELOA-AS1作为非小细胞肺癌早期诊断的潜在新生物标志物

目的：（肿瘤诱导血小板）TEPs在肿瘤发生的所有步骤中都扮演着积极的角色，通过转移肿瘤相关的生物分子，血小板与肿瘤细胞发生对抗，并导致这些生物分子的隔离。本研究旨在探讨TEPs lncRNA-STARD4-AS1和ELOA-AS1是否可能是NSCLC的潜在生物标志物。材料和方法：采用低速离心法制备TEPs。采用实时荧光定量PCR检测TEPs-STARD4-AS1、ELOA-AS1在训练组和验证组中的表达水平。生成ROC曲线评价其诊断价值。进一步分析TEPs-STARD4-AS1、ELOA-AS1与临床参数的相关性。结果：我们的研究结果显示，在两个队列中，与健康对照组相比，非小细胞肺癌患者的TEPs-STARD4-AS1和ELOA-AS1水平显著上调。通过ROC分析，我们发现TEPs-STARD4-AS1、ELOA-AS1对非小细胞肺癌患者具有较好的诊断价值（AUCSTARD4-AS1 = 0.800/0.774, AUCELOA-AS1 = 0.754/0.718分别用于对照诊断腺癌和鳞状细胞癌）。TEP-STARD4-AS1与ELOA-AS1联合检测可提高NSCLC的诊断效率。临床病理分析进一步显示，TEPs-STARD4-AS1表达水平与肿瘤淋巴结转移（TNM）分期显著相关（p = 0.011）， TEPs-ELOA-AS1表达水平与肿瘤淋巴结转移（TNM）分期及远处转移（p = 0.004）显著相关（p = 0.019）。结论：我们的数据表明TEPs-STARD4-AS1和ELOA-AS1是有希望的非侵入性非小细胞肺癌循环诊断标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Cancer Management and Research Medicine-Oncology

CiteScore

7.40

自引率

0.00%

发文量

448

审稿时长

16 weeks

期刊介绍： Cancer Management and Research is an international, peer reviewed, open access journal focusing on cancer research and the optimal use of preventative and integrated treatment interventions to achieve improved outcomes, enhanced survival, and quality of life for cancer patients. Specific topics covered in the journal include: ◦Epidemiology, detection and screening ◦Cellular research and biomarkers ◦Identification of biotargets and agents with novel mechanisms of action ◦Optimal clinical use of existing anticancer agents, including combination therapies ◦Radiation and surgery ◦Palliative care ◦Patient adherence, quality of life, satisfaction The journal welcomes submitted papers covering original research, basic science, clinical & epidemiological studies, reviews & evaluations, guidelines, expert opinion and commentary, and case series that shed novel insights on a disease or disease subtype.